Table of Contents Table of Contents
Previous Page  133 / 812 Next Page
Information
Show Menu
Previous Page 133 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

S129

Aims

To compare depressive, manic, and matched controls

regarding their sexuality.

Methods

The current study is an observational cross sectional

study, carried out on 173 women, among them 112 bipolar, diag-

nosed according to ICD-10 criteria (81 depressive, and 31 manic),

and 61 controls. All subjects fulfilled the Sexual Disorders Interview

(SDI), Female Sexual Function Index (FSFI) and to bipolar patients

BDI, YMRS have been administered.

Results

Female bipolar patients were significant less sexual

active than controls, depressivewomenbeing less interested in sex-

uality than manic patients; there were not significant differences

between the two patients’ samples regarding the frequency of sex-

ual intercourse, degree of psychopathology. Sexual problems on

FSFI were detected in 75% of bipolar patients, both bipolar groups

emphasizing difficulties in arousal, lubrication and sexual satisfac-

tion.

Conclusions

The issue of sexual problems in bipolar female

patients is delicate to investigate and often neglected, being dif-

ficult to ascertain to the mood disorder itself or to different

treatments the patients have been exposed to, or to stigma.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.155

EW38

A peripheral composite proteomic

and gene expression biomarker

related to diagnosis and affective state

in rapid cycling bipolar disorder

K. Munkholm

, M. Vinberg , L.V. Kessing

Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen,

Denmark

Corresponding author.

Introduction

Management of bipolar disorder is limited by

absence of laboratory test. While alterations related to multiple

biological pathways have been found in bipolar disorder, findings

have not translated into clinically applicable biomarkers. We pre-

viously found promise for a combined gene expression biomarker.

The combination of gene expression and proteomic biomarkers

could have potential as a meaningful clinical test.

Objectives

To identify a composite biomarker based on mul-

tiple potential peripheral biomarkers related to neuroplasticity,

inflammation and oxidative stress, both on a proteomic and gene

expression level.

Aims

To test the ability of a composite biomarker to discriminate

between bipolar disorder patients and healthy control subjects and

between affective states in bipolar disorder patients.

Methods

mRNA expression of a set of 19 candidate genes and

protein levels of immune markers and neurotrophic factors were

measured in peripheral blood mononuclear cells and combined

with urinary levels of oxidized nucleosides of 37 rapid cycling bipo-

lar disorder patients in different affective states (depression, mania

and euthymia) during a 6–12-month period and in 40 age- and

gender-matched healthy control subjects. A composite measure

was constructed in the first half of the sample and independently

validated in the second half of the sample. The composite measure

was evaluated using ROC curves and by calculating sensitivity and

specificity.

Results

Statistical analysis is ongoing. Results will be presented

at the congress.

Conclusions

Aperipheral composite biomarker based onmultiple

biological pathways on both proteomic and gene expression levels

may have potential as a clinically applicable biomarker.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.156

EW39

Ketamine effect of the neural

response of emotinal processing

H. Nießen

Leibniz Institute for Neurobiology, Clinical Affective Neuroimaging

Laboratory, Magdeburg, Germany

Introduction

The NMDA antagonist ketamine has shown a good

antidepressant effect in drug resistant patients with MDD. The

exact mechanism of these antidepressant effects are unknown but

some studies indicate that ketamine changes neuronal emotion

processing. Amygdala is an important brain structure for the emo-

tion processing in people with affective disorders. Previous studies

showed functional and morphological changes, for example ele-

vated neuronal activation in the amygdala in depressive patient.

Previous studies also indicated that ketamine seems to inhibit this

elevated amygdala function.

Methods

Sixty-three healthy subjects (28 female, group mean

age 25.65

±

4.32 years) took part in a double-blinded fMRI study.

Half of the participants received ketamine infusion with 0,5mg/kg

BW, and half received placebo (saline infusion). To investigate the

temporal development of the drug impact, the experiment was

repeated at three time points: baseline, one hour and 24 hours after

the infusion. We used a block design with positive and negative

facial expressions and forms (task adapted from Hariri [7]). Pre-

processing and statistical data analysis were performed in SPM8.

Results

We found a continuous suppression of the amygdala

during negative face recognition in the ketamine group, with a

maximum 24 hours after infusion.

Conclusion

Ketamine seems to inhibit amygdala function during

negative face perception.

Disclosure of interest

The author has not supplied his/her decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.157

EW40

Assessment of executive functions in

bipolar depression

R. Paunescu

, I. M

iclutia

Iuliu Hatieganu University of Medicine and Pharmacy,

Neurosciences, Cluj-Napoca, Romania

Corresponding author.

Introduction

Cognitive functions in bipolar disorder have been

assessed during acute mood episodes but also during remission.

While other cognitive functions, such as verbal and working mem-

ory, attention, verbal fluency and psychomotor speed seem to

recover after the acute episode, executive functions impairment

remains also during remission; this aspect led to the assumption

that executive functions may be a trait marker for bipolar disorder.

Objective

The purpose of this study was to assess the executive

functions, such as cognitive flexibility, set shifting, problem solving

and abstract thinking in bipolar depression compared to healthy

subjects.

Method

Forty patients diagnosed with Bipolar Disorder and

Major Depressive Episode according to DSM IV-TR were included

into the study. Executive functions were investigated using Wis-

consin Card Sorting Test (WCST). Results obtained by patients were

compared with those of 30 healthy who underwent the same cog-

nitive evaluation.

Results

Depressed bipolar patients scored significantly worse on

the majority of WCST measures. Thus, for total trials, total errors,

preservative errors andpreservative responses (rawscores andper-

cents) and failure to maintain set scores, the differences between

the two groups were significant at the 1% threshold (

P

= 0.000). The

patients and controls displayed similar behavior for total correct

(

P

= 0.215) and conceptual levels scores (

P

= 0.421).